A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma

Takeshita, Shigeyuki; Ichikawa, Tatsuki; Nakao, Kazuwa; Miyaaki, Hisamitsu; Shibata, Hidetaka; Matsuzaki, Takashi; Muraoka, Toru; Honda, Takeshi; Otani, M.; Akiyama, Motohisa; Miuma, Satoshi; Ozawa, Esuke; Fujimito, Masumi; Eguchi, Katsumi

doi:10.1016/j.nutres.2008.12.005

Cited by 48 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a recent retrospective study showed that oral BCAA supplementation after RFA improved 1 year (61.8% vs 52.0%) and 3-year (28.0% vs 12.0%) progression-free survival rates compared with a control group after RFA (P = 0.013) [80] . Oral BCAA supplementation after chemoembolization also prevents the decrease of liver function after treatment and improves the quality of life, although its ability to prevent HCC recurrence was not determined [81,82] . Oral BCAA treatment before chemoembolization was found useful in maintaining hepatic functional reserve [83] .…”

Section: Bcaas For Liver Cirrhosismentioning

confidence: 99%

Branched-chain amino acids in liver diseases

Tajiri¹,

Shimizu²

2018

Transl. Gastroenterol. Hepatol.

100

View full text Add to dashboard Cite

Branched chain amino acids (BCAAs) have been shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and insulin resistance. They have also been shown to inhibit the proliferation of liver cancer cells in vitro , and are essential for lymphocyte proliferation and dendritic cell maturation. In patients with advanced chronic liver disease, BCAA concentrations are low, whereas the concentrations of aromatic amino acids such as phenylalanine and tyrosine are high, conditions that may be closely associated with hepatic encephalopathy and the prognosis of these patients. Based on these basic observations, patients with advanced chronic liver disease have been treated clinically with BCAA-rich medicines, with positive effects.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Liver disease; Branched chain amino acids; Gene expression; Hepatocyte apoptosis; Hepatocyte regeneration; Immunity; Treatment Core tip: Advanced liver diseases are commonly accompanied by nutritional disturbances, which worsen the prognosis of the patients. Serum levels of branchedchain amino acids (BCAAs) are decreased in patients with liver cirrhosis, and the amino acids imbalance could affect the clinical picture of the disease and the prognosis of the patients. However, there are few comprehensive reviews on the biological activities of BCAAs. In this review, we summarize the biological activities of BCAAs, and discuss possible applications of BCAAs for the management of patients with advanced liver diseases with a list of clinical trials of BCAA administration.Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World

show abstract

Section: Bcaas For Liver Cirrhosismentioning

confidence: 99%

Branched-chain amino acids in liver diseases

Tajiri¹,

Shimizu²

2018

Transl. Gastroenterol. Hepatol.

100

View full text Add to dashboard Cite

show abstract

“…One trial of parenteral nutrition 53 and five of supplements [54][55][56][57][58] included patients with hepatocellular carcinoma. The current data do not compellingly justify the routine use of parenteral nutrition, enteral nutrition, or oral nutritional supplements in these patients.…”

Section: Nutrition Management In Terminal Stage Hepatocellular Carcinomamentioning

confidence: 99%

Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma

Kumar

Panda

2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…In the present study, we found that nutrient supplements with 210 kcal were rich in BCAAs and were optimal LES for patients with liver diseases. Regarding the supplementation periods, only one of the eight studies provided a short‐term supplementation intervention of 2 weeks; all the remaining studies provided a long‐term supplementation intervention. Our reviewed showed that long‐term administration is preferable to short‐term administration.…”

Section: Discussionmentioning

confidence: 99%

Significant effects of late evening snack on liver functions in patients with liver cirrhosis: A meta‐analysis of randomized controlled trials

Chen

Wang

Kuo

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Reducing post‐absorptive (fasting) phase by eating late evening snacks (LESs) is a potential intervention to improve substrate utilization and reverse sarcopenia. This study analyzed the results of published randomized controlled trials and controlled clinical trials to evaluate the effects of LES on liver function of patients with cirrhosis. Methods A meta‐analysis was conducted. The search strategy included electronic database searches, and 300 articles were searched. Eight of these articles provided qualified data for pooling and analysis. Outcomes assessments included serum albumin, total bilirubin, alanine aminotransferase, prothrombin time, and aspartate aminotransferase, complications of cirrhosis, severity of liver disease, and blood glucose levels. Results Our analysis included eight studies comprising 341 patients (167 in LES groups and 174 in control groups). The results showed that LES intervention helped to maintain liver reserves. These eight studies demonstrated that LES intervention had significant effects for liver biochemical parameters on albumin, ammonia, and prothrombin time, with respective effect sizes of 0.233, −0.425, and −0.589; liver enzymes include aspartate aminotransferase and alanine aminotransferase, with respective effect sizes of −0.320 and −0.284. Studies on clinical signs of liver dysfunction showed lower occurrence rates of ascites and hepatic encephalopathy than in the control group. LES had no significant effect on Child–Pugh score. Conclusions The overall results of the meta‐analysis indicated that having LES can improve liver function reserve for patients with liver cirrhosis, with or without hepatocellular carcinoma. LES is a promising intervention for reversing anabolic resistance and the sarcopenia of cirrhosis, resulting in an improved quality of life for patients with cirrhosis.

show abstract

A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma

Cited by 48 publications

References 32 publications

Branched-chain amino acids in liver diseases

Branched-chain amino acids in liver diseases

Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma

Significant effects of late evening snack on liver functions in patients with liver cirrhosis: A meta‐analysis of randomized controlled trials

Contact Info

Product

Resources

About